Form 4: Cyclerion Therapeutics CFO Reports Stock Transaction
Insider Transaction (Form 4)
Rhonda M. Chicko, Chief Financial Officer of Cyclerion Therapeutics, Inc., reported multiple transactions in common stock on August 14, 2026.
Summary
- Option exercise/conversion: acquired 25,000 Common Stock, no par value at $2.35 ($58,875) on August 14, 2026; holds 25,018 after (Direct).
- Option exercise/conversion: disposed of 25,000 Option to Purchase on August 14, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rhonda M. Chicko — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Option exercise/conversion | Common Stock, no par value | 25,000 | $2 | $58.9K | 25,018 |
| 2026-08-14 | Option exercise/conversion | Option to Purchase | 25,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Option exercise/conversion (25,000 shares) |
| 2026-08-14 | Option exercise/conversion (25,000 shares) |
Keywords
insider transaction, Form 4, CYCN, Cyclerion Therapeutics, Inc., neutral, Rhonda M. Chicko
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.